ECCO Topical Reviews
Access list of published ECCO Topical Reviews
Over the past years, ECCO has successfully published a considerable number of Consensus Guidelines on important topics of IBD. These guidelines will be updated on a regular basis; and there is the strong commitment to ensure user-friendliness. Thus ECCO is striving to contain the number of published Guidelines in order to avoid the publication of too many separate Guidelines manuscripts and to keep the information as concise as possible.
At the same time, the progress of research raises new topics, which ECCO is covering with the new series of publications “ECCO Topical Review”. These expert reviews are distinct from guideline papers and reserved to areas with yet limited evidence-based information. They focus on a particular topic related to the diagnosis, classification, or management of inflammatory bowel diseases and are authorised by ECCO by following the respective standard operating procedures. Expert opinion consensus endorsed by ECCO is the core feature of this procedure.
ECCO Topical Reviews: Current overview
Topics | Publication |
Fibrosis | February 2016 |
IBD in the Elderly | November 2016 |
Environmental Factors in IBD | December 2016 |
Research Gaps in Diet in IBD | August 2017 |
Transitional Care in IBD | February 2017 |
Exit Strategies for IBD Treatments |
August 2017 |
Complementary Medicine and Psychotherapy |
March 2019 |
Perioperative Dietary Therapy | September 2019 |
Optimising Reporting in Surgery, Endoscopy, and Histopathology |
January 2021 |
Clinopathological Spectrum & Differential Diagnosis |
Summer 2021 |
ECCO-ESGAR: Optimising Reporting in Cross-sectional Imaging | Summer 2021 |
Refractory IBD | Summer 2021 |
Roadmap to Perioperative Care in IBD | Spring 2022 |
Multidisciplinary Perinatal Care in IBD | May 2023 |
Biological Treatment Cycles in CD | July 2023 |
Predictive Models on IBD disease Course and Treatment Response | Late 2024 |
Pouch-related disorders | Early 2025 |
IBD-like patterns of drug colitis, with practical guidance and a focus on immune checkpoint inhibitors | Mid 2025 |
Optimisation in Therapy | Early 2026 |